Rita Turpin

This study shows Clever-1 inhibition disrupts mitochondrial function and lipid metabolism in AML, making it a potential therapeutic target.

The paper identifies microtubule inhibitors as inducers of immunogenic cell death in MYChigh TNBC, linking MYC-dependent DAMP release to immune activation and tumor protection.

This study identifies a secreted form of Clever-1 that suppresses T cell responses and reduces anti-PD-1 efficacy in cancer, suggesting it as a therapeutic target and biomarker.

The paper evaluates immunomodulatory drug responses in patient-derived tumor explant models of breast and renal cancer, finding reproducible gene expression and cytokine changes across models.